RXMD Company increased revenue from $13,642,704 in 2015 to $ 18,318,567 in 2016. That's a 34% increase;
Assets increased from $1,361,052 in 2015 to $2,610,167 in 2016. That's a 92% increase in assets (while liabilities increased only 63%);
Profit went from the 2015 net loss of $1,219,359 to the 2016 net income of $209,319, bringing the Total Stockholders' Deficit from (3,419,896) to (3,210,577);
< $18M+ in revenue, PROFITABLE, growing 34%/yr... and only $3.2M in TOTAL deficit --- absolutely fantastic, almost unheard of in penny stocks --- if you let anyone tell you that's looks bad, well, I'm sorry you don't read financial statements much and you therefore can't get comfortable with holding stocks for more than a day or a week (because you have NO CLUE what you're holding) >
And cash on hand went from $289,677 on Dec 31, 2015 to $816,220 on Dec 31, 2016 - that's a lot of cash on hand!
It doesn't take much time to see in the financial statements and throughout the report that everything Shital has put in the PR's about the business expansion - physical expansion AND services expansion AND revenue-producing business entity expansion - is where the rest of the profit is going... right back into the business for growth!
Do I think it's possible for the business to grow revenue by another 34%? After growing 34% last year? And 21% in 2015? And 21% in 2014?
Hmmm... SUBSTANTIAL GROWTH year over year, quarter over quarter, and the greatest growth this past year and that was BEFORE any significant contribution could be made from the high-efficiency robotic dispensing and the physical expansion and improvements. So where did it come from? Could it be that the company spoke truthfully all of last year about the various services that have been added and the impact they're having for attracting more and more high-margin customers and health service 'partners' (doctors, clinics, etc)? No doubt.
So, no - I think the company can do not only 34% growth this year, but the potential is there for much more. Organically? Absolutely, the 34% to 40% range is clearly possible, if not probably. However, with the strength Progressive Care & PharmCo has now, it's only a matter of time before a significant M&A move is made, IMO. So I look for growth to be higher.
Now, considering that revenue has grown in a big way, cash on-hand is fantastic, the company has access to capital for even more rapid expansion or other growth activities... and the stock is actually down 50% from when the compared had significantly lower revenues and had yet to show NET PROFITABILITY... and we have just BEGUN to see the effect of the business expansion...
Looks to me like shorts and naysayers have some conflicts to resolve... quickly. I just don't think the market's going to sit back and keep letting the little people dictate this artificially low price anymore.
But that's just my opinion, I think everyone ought to learn how to read financial statements and sort real information from biolerplate legal safe harbor statements... and sort the wheat from the chaff when it comes to "opinions." It's called DD, and it pays off well for those who put a little effort into it - gives you a little peace of mind when you can hold a strong position and let your money do the work FOR you. In a BIG way! That $1 price that I wrote about a year ago? Looks to me like we're in for some real progress in that direction.
News 
Market Data 
Discover 
